论文部分内容阅读
INTRODUCTIONrnDespite the advances made in the field of cancer therapeutics, treatment of metastatic disease remains a challenge and accounts for more than 90% of the breast cancer-related deaths world-wide.1 The median survival for patients with metastatic or late-stage breast cancer is between 2 and 4 years.2 Even though less than 10% of the newly diagnosed cases of breast cancer patients present with metastasis, 30%-50% of patients diagnosed with early-stage breast cancer eventually develop metastasis despite undergoing standard of care anticancer therapeutic regimens.